![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LYPD2 |
Gene summary for LYPD2 |
![]() |
Gene information | Species | Human | Gene symbol | LYPD2 | Gene ID | 137797 |
Gene name | LY6/PLAUR domain containing 2 | |
Gene Alias | LYPDC2 | |
Cytomap | 8q24.3 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | F1T0L0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
137797 | LYPD2 | HSIL_HPV_2 | Human | Cervix | HSIL_HPV | 1.49e-25 | 6.13e-01 | 0.0208 |
137797 | LYPD2 | H2 | Human | Cervix | HSIL_HPV | 1.05e-26 | 6.45e-01 | 0.0632 |
137797 | LYPD2 | LZE5T | Human | Esophagus | ESCC | 8.47e-11 | 1.92e+00 | 0.0514 |
137797 | LYPD2 | LZE20T | Human | Esophagus | ESCC | 4.98e-02 | 9.56e-01 | 0.0662 |
137797 | LYPD2 | C21 | Human | Oral cavity | OSCC | 2.07e-13 | 4.37e+00 | 0.2678 |
137797 | LYPD2 | C06 | Human | Oral cavity | OSCC | 7.41e-11 | 1.18e+00 | 0.2699 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | ![]() |
Skin | AK | ![]() |
Skin | SCCIS | ![]() |
Skin | cSCC | ![]() |
Thyroid | HT | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LYPD2 | SNV | Missense_Mutation | rs766328861 | c.4N>T | p.Arg2Trp | p.R2W | Q6UXB3 | protein_coding | tolerated(0.12) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LYPD2 | SNV | Missense_Mutation | rs766307085 | c.79N>A | p.Val27Ile | p.V27I | Q6UXB3 | protein_coding | deleterious(0) | benign(0.01) | TCGA-A6-6649-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | SD |
LYPD2 | SNV | Missense_Mutation | rs374454038 | c.86C>T | p.Pro29Leu | p.P29L | Q6UXB3 | protein_coding | tolerated(0.7) | benign(0) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LYPD2 | SNV | Missense_Mutation | rs781424827 | c.203N>T | p.Thr68Met | p.T68M | Q6UXB3 | protein_coding | deleterious(0.01) | probably_damaging(0.976) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LYPD2 | SNV | Missense_Mutation | rs369898532 | c.5G>A | p.Arg2Gln | p.R2Q | Q6UXB3 | protein_coding | tolerated(0.51) | benign(0) | TCGA-AP-A053-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LYPD2 | SNV | Missense_Mutation | rs765580069 | c.256N>A | p.Gly86Ser | p.G86S | Q6UXB3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D1-A174-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LYPD2 | SNV | Missense_Mutation | novel | c.101N>C | p.Val34Ala | p.V34A | Q6UXB3 | protein_coding | tolerated(0.25) | benign(0.019) | TCGA-D1-A175-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
LYPD2 | SNV | Missense_Mutation | novel | c.298N>G | p.Asn100Asp | p.N100D | Q6UXB3 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
LYPD2 | SNV | Missense_Mutation | rs748762835 | c.184N>A | p.Pro62Thr | p.P62T | Q6UXB3 | protein_coding | deleterious(0.01) | probably_damaging(0.969) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LYPD2 | SNV | Missense_Mutation | c.124N>T | p.Thr42Ser | p.T42S | Q6UXB3 | protein_coding | tolerated(0.12) | benign(0.197) | TCGA-L9-A8F4-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |